Rebiotix Begins Clinical Trial of Therapy for the Treatment of Recurrent Clostridium difficile-Associated Diarrhea

ROSEVILLE, Minn.--(BUSINESS WIRE)--Rebiotix Inc. has announced that physicians have treated the first patients as part of the PUNCH™ CD Phase 2 clinical trial of RBX2660 (microbiota suspension) for the treatment of recurrent Clostridium difficile-associated diarrhea (CDAD). RBX2660 represents the first drug product in the Rebiotix Microbiota Restoration Therapy (MRT) platform.

Help employers find you! Check out all the jobs and post your resume.